Abstract
Multinational companies (MNCs) have responded to India’s movement towards compliance with the WTO intellectual property agreement, TRIPS, by increasing the quantity and quality of foreign direct investment (FDI) in the areas of pharmaceutical research and development (R&D) and manufacturing. Drug prices do not necessarily provide an accurate signal of consumer’s preferences in all cases. However, it is not always clear why the market sustains high prices for some new drugs when cheaper alternatives of seemingly comparable quality are available. By contrast, MNCs have adopted a more cautious attitude toward patenting and commercialization of pharmaceutical products in India, waiting to see how Indian courts and patent office’s interpret the new laws, and awaiting the enactment of data exclusivity legislation
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
